York Biotech Campus-based Abingdon Health is expanding in the US after signing a lease to open a commercial office and laboratory in Madison, Wisconsin.
The site will commence operations in October 2024 and is expected to become fully operational in early 2025. This US footprint will enable Abingdon to provide additional CDMO (contract development and manufacturing organisation) support to its broadening international customer base and be closer to large customers in North America.
The USA is the largest medical device market in the world, comprising over 40% of the global medtech market and containing over 6,500 medtech companies. 30% of Abingdon’s revenues in the last financial year were derived from the United States.
The Group’s newly incorporated wholly owned subsidiary, Abingdon Health USA Inc, will operate from the University Research Park in Madison, Dane County, Wisconsin.
Chris Yates, CEO of Abingdon Health plc, said: “I’m looking forward to driving Abingdon’s worldwide commercial activities and, in particular, expanding our customer base in the US, the largest med-tech market globally.
“Our laboratory site in the US will mean we can offer US customers the opportunity to buy their services in the US; this is a first step for Abingdon to provide a broader CDMO proposition from within the US market.”
Lisa Johnson, CEO of BioForward Wisconsin, said: “On behalf of the biohealth community in Wisconsin, we welcome Abingdon Health to Madison. Abingdon Health is a leader in lateral flow diagnostic technology with a unique, end-to-end value proposition for its customers.
“As a publicly-traded UK company with a global presence, their decision to open a US office here in Wisconsin provides yet more evidence of our state’s growing stature in personalized medicine and biohealth technologies.
“We look forward to Abingdon Health complementing and strengthening our biohealth ecosystem, and bringing more economic impact and jobs to Wisconsin.”
